|
Characteristics in patients treated with mastectomy by type of adjuvant therapy received |
|||||
| Characteristic |
Adjuvant therapy |
Total (n = 2105) |
|||
|
|
|||||
| None (n = 956) |
Chemotherapy alone(n = 610) |
Radiotherapy alone (n = 143) |
Combined chemotherapy and radiotherapy (n = 396) |
||
|
|
|||||
| Age (years) |
|||||
| <35 |
14 (1.5) |
43 (7.1) |
4 (2.8) |
24 (6.0) |
85 (4.1) |
| 35–49 |
245 (25.6) |
390 (63.9) |
32 (22.4) |
251 (63.4) |
918 (43.6) |
| 50–64 |
404 (42.3) |
161 (26.4) |
64 (44.7) |
106 (26.8) |
735 (34.9) |
| >64 |
293 (30.6) |
16 (2.6) |
43 (30.1) |
15 (3.8) |
367 (17.4) |
| Ethnicity |
|||||
| Chinese |
831 (86.9) |
525 (86.1) |
126 (88.1) |
338 (85.4) |
1820 (86.5) |
| Malay |
65 (6.8) |
62 (10.2) |
9 (6.3) |
40 (10.1) |
176 (8.3) |
| Indian |
46 (4.8) |
19 (3.1) |
7 (4.9) |
14 (3.5) |
86 (4.1) |
| Other |
14 (1.5) |
4 (0.6) |
1 (0.7) |
4 (1.0) |
23 (1.1) |
| Menopausal status |
|||||
| Premenopausal |
242 (25.3) |
406 (66.6) |
35 (24.5) |
267 (67.4) |
950 (45.1) |
| Uncertain |
91 (9.5) |
76 (12.5) |
12 (8.4) |
25 (6.3) |
204 (9.7) |
| Postmenopausal |
623 (65.2) |
128 (20.9) |
96 (67.1) |
104 (26.3) |
951 (45.2) |
| ER/PR status |
|||||
| +/+ |
363 (47.1) |
176 (32.6) |
53 (45.7) |
95 (27.9) |
687 (38.9) |
| +/- |
139 (18.0) |
63 (11.7) |
29 (25.0) |
61 (17.9) |
292 (16.5) |
| -/+ |
41 (5.3) |
37 (6.8) |
2 (1.7) |
21 (6.2) |
101 (5.7) |
| -/- |
228 (29.6) |
264 (48.9) |
32 (27.6) |
163 (48.0) |
687 (38.9) |
| Not done |
185 |
70 |
27 |
56 |
338 |
| Pathologic T stage |
|||||
| T1 |
488 (51.1) |
209 (34.3) |
38 (26.6) |
70 (17.7) |
805 (38.2) |
| T2 |
423 (44.3) |
368 (60.3) |
83 (58.0) |
249 (62.9) |
1123 (53.4) |
| T3 |
45 (4.7) |
33 (5.4) |
22 (15.4) |
77 (19.4) |
177 (8.4) |
| Lymph node (N) status |
|||||
| Positive |
243 (25.4) |
300 (49.2) |
74 (51.8) |
339 (85.6) |
956 (45.4) |
| Negative |
713 (74.6) |
310 (50.8) |
69 (48.2) |
57 (14.4) |
1149 (54.6) |
| Histological grading |
|||||
| Well |
164 (21.2) |
49 (8.8) |
17 (13.3) |
21 (5.7) |
251 (13.8) |
| Moderate |
369 (47.7) |
218 (39.2) |
57 (44.5) |
125 (34.1) |
769 (42.2) |
| Poor |
240 (31.1) |
289 (52.0) |
54 (42.2) |
221 (60.2) |
804 (44.1) |
| Not done |
183 |
54 |
15 |
29 |
281 |
|
Values are expressed as number (%). ER, oestrogen receptor; PR, progesterone receptor. | |||||
Gao et al. Breast Cancer Research 2007 9:R21 doi:10.1186/bcr1658 |
|||||